Skip to main content
SpringerLink
Log in

Propofol Infusion Syndrome

An Overview of a Perplexing Disease

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent that is widely used in adults and children for sedation and the induction and maintenance of anaesthesia. Propofol has gained popularity for its rapid onset and rapid recovery even after prolonged use, and for the neuroprotection conferred. However, a review of the literature reveals multiple instances in which prolonged propofol administration (>48 hours) at high doses (>4 mg/kg/h) may cause a rare, but frequently fatal complication known as propofol infusion syndrome (PRIS). PRIS is characterized by metabolic acidosis, rhabdomyolysis of both skeletal and cardiac muscle, arrhythmias (bradycardia, atrial fibrillation, ventricular and supraventricular tachycardia, bundle branch block and asystole), myocardial failure, renal failure, hepatomegaly and death. PRIS has been described as an ‘all or none’ syndrome with sudden onset and probable death. The literature does not provide evidence of degrees of symptoms, nor of mildness or severity of signs in the clinical course of the syndrome. Recently, a fatal case of PRIS at a low infusion rate (1.9–2.6 mg/kg/h) has been reported.

Common laboratory and instrumental findings in PRIS are myoglobinuria, downsloping ST-segment elevation, an increase in plasma creatine kinase, troponin I, potassium, creatinine, azotaemia, malonylcarnitine and C5-acylcarnitine, whereas in the mitochondrial respiratory electron transport chain, the activity of complex IV and cytochrome oxidase ratio is reduced. Propofol should be used with caution for sedation in critically ill children and adults, as well as for longterm anesthesia in otherwise healthy patients, and doses exceeding 4–5 mg/kg/h for long periods (>48 h) should be avoided. If PRIS is suspected, propofol must be stopped immediately and cardiocirculatory stabilization and correction of metabolic acidosis initiated. So, PRIS must be kept in mind as a rare, but highly lethal, complication of propofol use, not necessarily confined to its prolonged use. Furthermore, the safe dosage of propofol may need re-evaluation, and new studies are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Carli F, Mistraletti G. Metabolic and endocrine effects of sedative agents. Minerva Anestesiol 2006; 72: 395–9

    PubMed  CAS  Google Scholar 

  2. Ito H, Watanabe Y, Isshiki A, et al. Neuroprotective properties of propofol and midazolam, but not pentobarbital, on neuronal damage induced by forebrain ischemia, based on the GABAA receptors. Acta Anaesthesiol Scand 1999; 43: 153–62

    Article  PubMed  CAS  Google Scholar 

  3. Sitar SM, Hanifi-Moghaddam P, Gelb A, et al. Propofol prevents peroxide-induced inhibition of glutamate transport in cultured astrocytes. Anesthesiology 1999; 90: 1446–53

    Article  PubMed  CAS  Google Scholar 

  4. Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des 2004; 10: 3639–49

    Article  PubMed  CAS  Google Scholar 

  5. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America’s Working Group on Status Epilepticus. JAMA 1993; 270: 854–9

    Article  Google Scholar 

  6. Kelly DF. Propofol-infusion syndrome. J Neurosurg 2001; 95: 925–6

    Article  PubMed  CAS  Google Scholar 

  7. Sanchez-Izquierdo-Riera JA, Caballero-Cubedo RE, Perez-Vela JL, et al. Propofol versus midazolam: safety and efficacy for sedating the severe trauma patient. Anesth Analg 1998; 86: 1219–24

    PubMed  CAS  Google Scholar 

  8. Ronan KP, Gallagher TJ, George B, et al. Comparison of propofol and midazolam for sedation in intensive care unit patients. Crit Care Med 1995; 23: 286–93

    Article  PubMed  CAS  Google Scholar 

  9. Barrientos-Vega R, Mar Sánchez-Soria M, Morales-García C, et al. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med 1997; 25: 33–40

    Article  PubMed  CAS  Google Scholar 

  10. Carrasco G, Molina R, Costa J, et al. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients: a cost-benefit analysis. Chest 1993; 103: 557–64

    Article  PubMed  CAS  Google Scholar 

  11. Vasile B, Rasulo F, Candiani A, et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003; 29: 1417–25

    Article  PubMed  Google Scholar 

  12. Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology 1998; 50: 301–3

    Article  PubMed  CAS  Google Scholar 

  13. Wolf A, Weir P, Segar P, et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001; 357: 606–7

    Article  PubMed  CAS  Google Scholar 

  14. Cremer OL, Moons KG, Bouman EA, et al. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001; 357: 117–8

    Article  PubMed  CAS  Google Scholar 

  15. Eriksen J, Povey HM. A case of suspected non-neurosurgical adult fatal propofol infusion syndrome. Acta Anaesthesiol Scand 2006; 50: 117–9

    Article  PubMed  CAS  Google Scholar 

  16. Kang TM. Propofol infusion syndrome in critically ill patients. Ann Pharmacother 2002; 36: 1453–6

    Article  PubMed  Google Scholar 

  17. Bray RJ. Fatal myocardial failure associated with a propofol infusion in a child [letter]. Anaesthesia 1995; 50: 94

    Article  PubMed  CAS  Google Scholar 

  18. Culp KE, Augoustides JG, Ochroch AE, et al. Clinical management of cardiogenic shock associated with prolonged propofol infusion. Anesth Analg 2004; 99: 221–6

    Article  PubMed  Google Scholar 

  19. De Cosmo G, Congedo E, Clemente A, et al. Sedation in PACU: the role of propofol. Curr Drug Targets 2005; 6: 741–4

    Article  PubMed  Google Scholar 

  20. Cannon ML, Glazier SS, Bauman LA. Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion. J Neurosurg 2001; 95: 1053–6

    Article  PubMed  CAS  Google Scholar 

  21. Stelow EB, Johari VP, Smith SA, et al. Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and anatomic findings. Clin Chem 2000; 46: 577–81

    PubMed  CAS  Google Scholar 

  22. Casserly B, O’Mahony E, Timm EG, et al. Propofol infusion syndrome: an unusual cause of renal failure. Am J Kidney Dis 2004; 44: 98–101

    Article  Google Scholar 

  23. Ahlen K, Buckley CJ, Goodale DB, et al. The ‘propofol infusion syndrome’: the facts, their interpretation and implications for patient care. Eur J Anaesthesiol 2006; 23: 990–8

    Article  PubMed  CAS  Google Scholar 

  24. Motsch J, Roggenbach J. Propofol infusion syndrome. Anaesthesist 2004; 53: 1009–22

    Article  PubMed  CAS  Google Scholar 

  25. Liolios A, Guerit JM, Scholtes JL, et al. Propofol infusion syndrome associated with short-term large-dose infusion during surgical anesthesia in an adult. Anesth Analg 2005; 100: 1804–6 303

    Article  PubMed  Google Scholar 

  26. Merz TM, Regli B, Rothen HU, et al. Propofol infusion syndrome: a fatal case at a low infusion rate [letter]. Anesth Analg 2006; 103: 1050

    Article  PubMed  Google Scholar 

  27. Salengros J, Engelman E. Metabolic acidosis due to propofol infusion. Anesthesiology 2005; 102: 698–9

    Article  Google Scholar 

  28. Burow BK, Johnson ME, Packer DL. Metabolic acidosis associated with propofol in the absence of other causative factors. Anesthesiology 2004; 101: 239–41

    Article  PubMed  Google Scholar 

  29. Parke TJ, Stevens JE, Rice AS, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992; 305: 613–6

    Article  PubMed  CAS  Google Scholar 

  30. Barclay K, Williams AJ, Major E. Propofol infusion in children. BMJ 1992; 305: 953–4

    Article  PubMed  CAS  Google Scholar 

  31. Bodd E, Endresen L. Use of propofol for children. Tidsskr Nor Laegeforen 1992; 112: 1636–7

    Google Scholar 

  32. Strickland RA, Murray MJ. Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship? Crit Care Med 1995; 23: 405–9

    Article  PubMed  CAS  Google Scholar 

  33. Plotz FB, Waalkens HJ, Verkade HJ, et al. Fatal side-effects of continuous propofol infusion in children may be related to malignant hyperthermia. Anaesth Intensive Care 1996; 24:724

    PubMed  CAS  Google Scholar 

  34. Cray SH, Robinson BH, Cox PN. Lactic acidemia and bradyarrhythmia in a child sedated with propofol. Crit Care Med 1998; 26: 2087–92

    Article  PubMed  CAS  Google Scholar 

  35. Withington DE, Decell MK, Al Ayed T. A case of propofol toxicity: further evidence for a causal mechanism. Paediatr Anaesth 2004; 14: 505–8

    Article  PubMed  Google Scholar 

  36. Holzki J, Aring C, Gillor A. Death after re-exposure to propofol in a 3-year-old child: a case report. Paediatr Anaesth 2004; 14: 265–70

    Article  PubMed  Google Scholar 

  37. Marinella MA. Lactic acidosis associated with propofol. Chest 1996; 109: 292

    Article  PubMed  CAS  Google Scholar 

  38. Perrier ND, Baerga-Varela Y, Murray MJ. Death related to propofol use in an adult patient. Crit Care Med 2000; 28: 3071–4

    Article  PubMed  CAS  Google Scholar 

  39. Friedman JA, Manno E, Fulgham JR. Propofol. J Neurosurg 2002; 96: 1161–2

    PubMed  Google Scholar 

  40. Ernest D, French C. Propofol infusion syndrome: report of an adult fatality. Anaesth Intensive Care 2003; 31: 316–9

    PubMed  CAS  Google Scholar 

  41. Kumar MA, Urrutia VC, Thomas CE, et al. The syndrome of irreversible acidosis after prolonged propofol infusion. Neurocrit Care 2005; 3: 257–9

    Article  PubMed  Google Scholar 

  42. Corbett SM, Moore J, Rebuck JA, et al. Survival of propofol infusion syndrome in a head-injured patient. Crit Care Med 2006; 34: 2479–83

    Article  PubMed  CAS  Google Scholar 

  43. Karakitsos D, Poularas J, Kalogeromitros A, et al. The propofol infusion syndrome treated with haemofiltration: is there a time for genetic screening? Acta Anaesthesiol Scand 2007; 51: 644–5

    Article  PubMed  CAS  Google Scholar 

  44. Fudickar A, Bein B, Tonner PH. Propofol infusion syndrome in anaesthesia and intensive care medicine. Curr Opin Anaesthesiol 2006; 19: 404–10

    Article  PubMed  Google Scholar 

  45. Mehta N, DeMunter C, Habibi P, et al. Short-term propofol infusions in children. Lancet 1999; 354: 866–7

    Article  PubMed  CAS  Google Scholar 

  46. Schenkman KA, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med 2000; 28: 172–7

    Article  PubMed  CAS  Google Scholar 

  47. Hansen TG. Propofol infusion syndrome in children. Ugeskr Laeger 2005; 167: 3672–5

    PubMed  Google Scholar 

  48. Makiguchi M, Kawaguchi H, Tamura M, et al. Effect of palmitic acid and fatty acid binding protein on ventricular fibrillation threshold in the perfused rat heart. Cardiovasc Drugs Ther 1991; 5: 753–61

    Article  PubMed  CAS  Google Scholar 

  49. Makiguchi M. Studies on the mechanism of arrhythmogenic action of free fatty acid. Hokkaido Igaku Zasshi 1988; 63: 624–34

    PubMed  CAS  Google Scholar 

  50. Zhou W, Fontenot HJ, Wang SN, et al. Propofol-induced alterations in myocardial beta-adrenoceptor binding and responsiveness. Anesth Analg 1999; 89: 604–8

    PubMed  CAS  Google Scholar 

  51. Feillet F, Steinmann G, Vianey-Saban C, et al. Adult presentation of MCAD deficiency revealed by coma and severe arrythmias. Intensive Care Med 2003; 29: 1594–7

    Article  PubMed  CAS  Google Scholar 

  52. Maier EM, Liebl B, Roschinger W, et al. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat 2005; 25: 443–52

    Article  PubMed  CAS  Google Scholar 

  53. Farag E, Deboer G, Cohen BH, et al. Metabolic acidosis due to propofol infusion. Anesthesiology 2005; 102: 697–8

    Article  PubMed  Google Scholar 

  54. Short TG, Young Y. Toxicity of intravenous anaesthetics. Best Pract Res Clin Anaesthesiol 2003; 17: 77–89

    Article  PubMed  CAS  Google Scholar 

  55. Myburgh JA, Upton RN, Grant C, et al. Epinephrine, norepinephrine and dopamine infusions decrease propofol concentrations during continuous propofol infusion in an ovine model. Intensive Care Med 2001; 27: 276–82

    Article  PubMed  CAS  Google Scholar 

  56. Wolf AR, Potter F. Propofol infusion in children: when does an anesthetic tool become an intensive care liability? Paediatr Anaesth 2004; 14: 435–8

    Article  PubMed  Google Scholar 

  57. Vernooy K, Delhaas T, Cremer OL, et al. Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm 2006; 3: 131–7

    Article  PubMed  Google Scholar 

  58. Branca D, Vincenti E, Scutari G. Influence of the anesthetic 2,6-diisopropylphenol (propofol) on isolated rat heart mitochondria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995; 110: 41–5

    Article  PubMed  CAS  Google Scholar 

  59. Liskaser FJ, Bellomo R, Hayhoe M, et al. The role of pump prime in the etiology and pathogenesis of cardiopulmonary bypass-associated acidosis. Anesthesiology 2000; 93: 1170–3

    Article  PubMed  CAS  Google Scholar 

  60. Lindner, Zierz S. Rhabdomyolysis and myoglobinuria. Nervenarzt 2003; 74: 505–15

    PubMed  CAS  Google Scholar 

  61. Reed MD, Blumer JL. Propofol bashing: the time to stop is now! Crit Care Med 1996; 24: 175–7

    Article  PubMed  CAS  Google Scholar 

  62. Enting D, Ligtenberg JJ, Aarts LP, et al. Total suppression of cerebral activity by thiopental mimicking propofol infusion syndrome: a fatal common pathway? Anesth Analg 2005; 100: 1864–5

    Article  PubMed  Google Scholar 

  63. Astrazeneca. Letter to health care provider [online]. Available from URL: http://www.fda.gov/medwatch/safety/2001/diprivan_deardoc.pdf [Accessed 2008 Mar 3]

  64. Wooltorton E. Propofol: contraindicated for sedation of pediatric intensive care patients [letter]. CMAJ 2002; 167: 507

    PubMed  Google Scholar 

  65. Tobias JD. Sedation and analgesia in the pediatric intensive care unit. Pediatr Ann 2005; 34: 636–45

    PubMed  Google Scholar 

  66. Angelini G, Ketzler JT, Coursin DB. Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit. Crit Care Clin 2001; 17:863–80

    Article  PubMed  CAS  Google Scholar 

  67. Leone M, Visintini P, Alliez JR, et al. What sedation for prevention and treatment secondary brain insult? Ann Fr Anesth Reanim 2006; 25: 852–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Support for this work was provided solely from departmental sources; therefore, it is free from any sources of funding. There are no financial relationships between the authors and any commercial entity with a vested interest in this review.

Author information

Authors and Affiliations

  1. Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Policlinico Universitario, via C. Valeria, Messina, 98125, Italy

    Vincenzo Fodale & Enza La Monaca

Authors
  1. Vincenzo Fodale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enza La Monaca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Fodale.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fodale, V., La Monaca, E. Propofol Infusion Syndrome. Drug-Safety 31, 293–303 (2008). https://doi.org/10.2165/00002018-200831040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831040-00003

Keywords

Search

Navigation